Roth Mkm Begins Coverage on Gain Therapeutics (NASDAQ:GANX)

Investment analysts at Roth Mkm started coverage on shares of Gain Therapeutics (NASDAQ:GANX) in a research note issued to investors on Friday, MarketBeat reports. The brokerage set a “buy” rating and a $7.00 price target on the stock. Roth Mkm’s target price indicates a potential upside of 291.06% from the company’s current price.

Other equities research analysts have also recently issued research reports about the company. HC Wainwright reiterated a “buy” rating and issued a $8.00 price objective on shares of Gain Therapeutics in a research note on Monday, November 25th. Oppenheimer reiterated an “outperform” rating and issued a $8.00 price objective on shares of Gain Therapeutics in a research note on Wednesday, August 14th. Finally, Chardan Capital reiterated a “buy” rating and issued a $6.00 price objective on shares of Gain Therapeutics in a research note on Friday, August 9th. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $7.25.

Gain Therapeutics Price Performance

Shares of NASDAQ GANX opened at $1.79 on Friday. The company has a current ratio of 2.99, a quick ratio of 2.99 and a debt-to-equity ratio of 0.04. Gain Therapeutics has a twelve month low of $0.89 and a twelve month high of $5.33. The stock has a 50 day moving average of $2.09 and a two-hundred day moving average of $1.68. The stock has a market cap of $47.47 million, a P/E ratio of -1.63 and a beta of 0.21.

Institutional Investors Weigh In On Gain Therapeutics

Several large investors have recently modified their holdings of the stock. Hohimer Wealth Management LLC purchased a new stake in shares of Gain Therapeutics during the second quarter worth approximately $422,000. Geode Capital Management LLC raised its stake in shares of Gain Therapeutics by 48.0% during the third quarter. Geode Capital Management LLC now owns 271,972 shares of the company’s stock worth $484,000 after purchasing an additional 88,236 shares during the last quarter. Renaissance Technologies LLC raised its stake in shares of Gain Therapeutics by 154.2% during the second quarter. Renaissance Technologies LLC now owns 118,700 shares of the company’s stock worth $152,000 after purchasing an additional 72,000 shares during the last quarter. Finally, Warberg Asset Management LLC purchased a new stake in shares of Gain Therapeutics during the second quarter worth approximately $66,000. Hedge funds and other institutional investors own 11.97% of the company’s stock.

About Gain Therapeutics

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.